<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156555">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02122692</url>
  </required_header>
  <id_info>
    <org_study_id>15820A</org_study_id>
    <secondary_id>2013-003597-27</secondary_id>
    <nct_id>NCT02122692</nct_id>
  </id_info>
  <brief_title>Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects</brief_title>
  <official_title>Interventional, Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the effect of the strong CYP3A4/5 inhibitor itraconazole (200 mg QD) on the
      multipledose exposure of Lu AE58054 (30 mg QD) in healthy subjects (CYP2D6 extensive
      metabolisers).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the Lu AE58054 plasma concentration-time curve from time zero to 24 hours post-dose (AUC0-24)</measure>
    <time_frame>Day 5 and Day 11</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of Lu AE58054</measure>
    <time_frame>Day 5 and Day 11</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics for Lu AE58054: AUC0-24, Cmax, time at which maximum observed plasma concentration occurred (tmax), apparent oral clearance (CL/F), half life (t½) and apparent volume of distribution Vz/F</measure>
    <time_frame>Day 5 and Day 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics for relevant metabolites: AUC0-24, Cmax, tmax, t½ and metabolic ratio (MR)</measure>
    <time_frame>Day 5 and Day 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic parameters for itraconazole: CTrough</measure>
    <time_frame>Day 6 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to Day 18, including a safety follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (C-SSRS) categorization based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions</measure>
    <time_frame>Up to Day 18, including a safety follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Lu AE58054 30 mg + itraconazole 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AE58054 30 mg</intervention_name>
    <description>Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally</description>
    <arm_group_label>Lu AE58054 30 mg + itraconazole 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AE58054 30 mg + itraconazole 200 mg</intervention_name>
    <description>Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally</description>
    <arm_group_label>Lu AE58054 30 mg + itraconazole 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole capsules, once daily, Day 12-13, orally</description>
    <arm_group_label>Lu AE58054 30 mg + itraconazole 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects are eligible for inclusion into the study if they meet each of the following
        criteria:

          -  Men and women, aged 18 - 45 years.

          -  Body weight at least 50 kg and Body Mass index 19 - 28 kg/m2.

          -  Good general health ascertained by a detailed medical history, laboratory tests and
             physical examination.

          -  Non-childbearing potential or use of contraception (both sexes).

          -  Women must not be pregnant or lactating.

          -  Known CYP2D6 genotype (Extensive metaboliser (n=15) and poor metaboliser (n =5)) .

        Other Inclusion and Exclusion Criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <email>LundbeckClinicalTrials@lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>FR801</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>April 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
